|
Fusion Gene Summary | |
Fusion Gene ORF analysis | |
Fusion Genomic Features | |
Fusion Protein Features | |
Fusion Gene Sequence | |
Fusion Gene PPI analysis | |
Related Drugs | |
Related Diseases |
Fusion gene:FGFR2-FGFR2 (FusionGDB2 ID:HG2263TG2263) |
Fusion Gene Summary for FGFR2-FGFR2 |
Fusion gene summary |
Fusion gene information | Fusion gene name: FGFR2-FGFR2 | Fusion gene ID: hg2263tg2263 | Hgene | Tgene | Gene symbol | FGFR2 | FGFR2 | Gene ID | 2263 | 2263 |
Gene name | fibroblast growth factor receptor 2 | fibroblast growth factor receptor 2 | |
Synonyms | BBDS|BEK|BFR-1|CD332|CEK3|CFD1|ECT1|JWS|K-SAM|KGFR|TK14|TK25 | BBDS|BEK|BFR-1|CD332|CEK3|CFD1|ECT1|JWS|K-SAM|KGFR|TK14|TK25 | |
Cytomap | ('FGFR2')('FGFR2') 10q26.13 | 10q26.13 | |
Type of gene | protein-coding | protein-coding | |
Description | fibroblast growth factor receptor 2BEK fibroblast growth factor receptorbacteria-expressed kinasekeratinocyte growth factor receptorprotein tyrosine kinase, receptor like 14 | fibroblast growth factor receptor 2BEK fibroblast growth factor receptorbacteria-expressed kinasekeratinocyte growth factor receptorprotein tyrosine kinase, receptor like 14 | |
Modification date | 20200322 | 20200322 | |
UniProtAcc | P21802 | P21802 | |
Ensembl transtripts involved in fusion gene | ENST00000346997, ENST00000351936, ENST00000356226, ENST00000357555, ENST00000358487, ENST00000360144, ENST00000369056, ENST00000369059, ENST00000369060, ENST00000369061, ENST00000457416, ENST00000478859, ENST00000359354, ENST00000490349, | ENST00000346997, ENST00000351936, ENST00000356226, ENST00000357555, ENST00000358487, ENST00000359354, ENST00000360144, ENST00000369056, ENST00000369059, ENST00000369060, ENST00000369061, ENST00000457416, ENST00000478859, ENST00000490349, | |
Fusion gene scores | * DoF score | 24 X 20 X 12=5760 | 11 X 11 X 8=968 |
# samples | 38 | 16 | |
** MAII score | log2(38/5760*10)=-3.92199748799873 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(16/968*10)=-2.59693514238723 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
Context | PubMed: FGFR2 [Title/Abstract] AND FGFR2 [Title/Abstract] AND fusion [Title/Abstract] | ||
Most frequent breakpoint | FGFR2(123243211)-FGFR2(123259078), # samples:1 FGFR2(123263358)-FGFR2(123256081), # samples:1 FGFR2(123239149)-FGFR2(123239471), # samples:1 | ||
Anticipated loss of major functional domain due to fusion event. |
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
Partner | Gene | GO ID | GO term | PubMed ID |
Hgene | FGFR2 | GO:0008284 | positive regulation of cell proliferation | 8663044 |
Hgene | FGFR2 | GO:0008543 | fibroblast growth factor receptor signaling pathway | 8663044|15629145 |
Hgene | FGFR2 | GO:0018108 | peptidyl-tyrosine phosphorylation | 15629145|16844695 |
Hgene | FGFR2 | GO:0046777 | protein autophosphorylation | 15629145 |
Tgene | FGFR2 | GO:0008284 | positive regulation of cell proliferation | 8663044 |
Tgene | FGFR2 | GO:0008543 | fibroblast growth factor receptor signaling pathway | 8663044|15629145 |
Tgene | FGFR2 | GO:0018108 | peptidyl-tyrosine phosphorylation | 15629145|16844695 |
Tgene | FGFR2 | GO:0046777 | protein autophosphorylation | 15629145 |
Fusion gene information * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
Source | Disease | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
Top |
Fusion Gene ORF analysis for FGFR2-FGFR2 |
Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
ORFfinder result based on the fusion transcript sequence of in-frame fusion genes. |
Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | Seq length (transcript) | BP loci (transcript) | Predicted start (transcript) | Predicted stop (transcript) | Seq length (amino acids) |
DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated. |
Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | No-coding score | Coding score |
Top |
Fusion Genomic Features for FGFR2-FGFR2 |
FusionAI prediction of the potential fusion gene breakpoint based on the pre-mature RNA sequence context (+/- 5kb of individual partner genes, total 20kb length sequence). FusionAI is a fusion gene breakpoint classifier based on convolutional neural network by comparing the fusion positive and negative sequence context of ~ 20K fusion gene data. From here, we can have the relative potentency of the 20K genomic sequence how individual sequnce will be likely used as the gene fusion breakpoints. |
Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | 1-p | p (fusion gene breakpoint) |
Top |
Fusion Protein Features for FGFR2-FGFR2 |
Four levels of functional features of fusion genes Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/:123243211/:123259078) - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. - How to search 1. Put your fusion gene symbol. 2. Press the tab key until there will be shown the breakpoint information filled. 4. Go down and press 'Search' tab twice. 4. Go down to have the hyperlink of the search result. 5. Click the hyperlink. 6. See the FGviewer result for your fusion gene. |
Main function of each fusion partner protein. (from UniProt) |
Hgene | Tgene |
FGFR2 | FGFR2 |
FUNCTION: Tyrosine-protein kinase that acts as cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of cell proliferation, differentiation, migration and apoptosis, and in the regulation of embryonic development. Required for normal embryonic patterning, trophoblast function, limb bud development, lung morphogenesis, osteogenesis and skin development. Plays an essential role in the regulation of osteoblast differentiation, proliferation and apoptosis, and is required for normal skeleton development. Promotes cell proliferation in keratinocytes and immature osteoblasts, but promotes apoptosis in differentiated osteoblasts. Phosphorylates PLCG1, FRS2 and PAK4. Ligand binding leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate. Phosphorylation of FRS2 triggers recruitment of GRB2, GAB1, PIK3R1 and SOS1, and mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. FGFR2 signaling is down-regulated by ubiquitination, internalization and degradation. Mutations that lead to constitutive kinase activation or impair normal FGFR2 maturation, internalization and degradation lead to aberrant signaling. Over-expressed FGFR2 promotes activation of STAT1. {ECO:0000269|PubMed:12529371, ECO:0000269|PubMed:15190072, ECO:0000269|PubMed:15629145, ECO:0000269|PubMed:16384934, ECO:0000269|PubMed:16597617, ECO:0000269|PubMed:17311277, ECO:0000269|PubMed:17623664, ECO:0000269|PubMed:18374639, ECO:0000269|PubMed:19103595, ECO:0000269|PubMed:19387476, ECO:0000269|PubMed:19410646, ECO:0000269|PubMed:21596750, ECO:0000269|PubMed:8663044}. | FUNCTION: Tyrosine-protein kinase that acts as cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of cell proliferation, differentiation, migration and apoptosis, and in the regulation of embryonic development. Required for normal embryonic patterning, trophoblast function, limb bud development, lung morphogenesis, osteogenesis and skin development. Plays an essential role in the regulation of osteoblast differentiation, proliferation and apoptosis, and is required for normal skeleton development. Promotes cell proliferation in keratinocytes and immature osteoblasts, but promotes apoptosis in differentiated osteoblasts. Phosphorylates PLCG1, FRS2 and PAK4. Ligand binding leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate. Phosphorylation of FRS2 triggers recruitment of GRB2, GAB1, PIK3R1 and SOS1, and mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. FGFR2 signaling is down-regulated by ubiquitination, internalization and degradation. Mutations that lead to constitutive kinase activation or impair normal FGFR2 maturation, internalization and degradation lead to aberrant signaling. Over-expressed FGFR2 promotes activation of STAT1. {ECO:0000269|PubMed:12529371, ECO:0000269|PubMed:15190072, ECO:0000269|PubMed:15629145, ECO:0000269|PubMed:16384934, ECO:0000269|PubMed:16597617, ECO:0000269|PubMed:17311277, ECO:0000269|PubMed:17623664, ECO:0000269|PubMed:18374639, ECO:0000269|PubMed:19103595, ECO:0000269|PubMed:19387476, ECO:0000269|PubMed:19410646, ECO:0000269|PubMed:21596750, ECO:0000269|PubMed:8663044}. |
Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at * Minus value of BPloci means that the break pointn is located before the CDS. |
- In-frame and retained protein feature among the 13 regional features. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
- In-frame and not-retained protein feature among the 13 regional features. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Top |
Fusion Gene Sequence for FGFR2-FGFR2 |
For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. To have fusion amino acid sequence, we ran ORFfinder and chose the longest ORF among the all predicted ones. |
Top |
Fusion Gene PPI Analysis for FGFR2-FGFR2 |
Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in |
Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
Hgene | Hgene's interactors | Tgene | Tgene's interactors |
- Retained PPIs in in-frame fusion. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
- Lost PPIs in in-frame fusion. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
- Retained PPIs, but lost function due to frame-shift fusion. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
Related Drugs for FGFR2-FGFR2 |
Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.8 2021-05-08) |
Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Hgene | FGFR2 | P21802 | DB00039 | Palifermin | Agonist|Binder | Biotech | Approved |
Hgene | FGFR2 | P21802 | DB00039 | Palifermin | Agonist|Binder | Biotech | Approved |
Hgene | FGFR2 | P21802 | DB00039 | Palifermin | Agonist|Binder | Biotech | Approved |
Hgene | FGFR2 | P21802 | DB00039 | Palifermin | Agonist|Binder | Biotech | Approved |
Hgene | FGFR2 | P21802 | DB08896 | Regorafenib | Inhibitor | Small molecule | Approved |
Hgene | FGFR2 | P21802 | DB08896 | Regorafenib | Inhibitor | Small molecule | Approved |
Hgene | FGFR2 | P21802 | DB08896 | Regorafenib | Inhibitor | Small molecule | Approved |
Hgene | FGFR2 | P21802 | DB08896 | Regorafenib | Inhibitor | Small molecule | Approved |
Hgene | FGFR2 | P21802 | DB09079 | Nintedanib | Inhibitor | Small molecule | Approved |
Hgene | FGFR2 | P21802 | DB09079 | Nintedanib | Inhibitor | Small molecule | Approved |
Hgene | FGFR2 | P21802 | DB09079 | Nintedanib | Inhibitor | Small molecule | Approved |
Hgene | FGFR2 | P21802 | DB09079 | Nintedanib | Inhibitor | Small molecule | Approved |
Hgene | FGFR2 | P21802 | DB10770 | Foreskin fibroblast (neonatal) | Agonist | Biotech | Approved |
Hgene | FGFR2 | P21802 | DB10770 | Foreskin fibroblast (neonatal) | Agonist | Biotech | Approved |
Hgene | FGFR2 | P21802 | DB10770 | Foreskin fibroblast (neonatal) | Agonist | Biotech | Approved |
Hgene | FGFR2 | P21802 | DB10770 | Foreskin fibroblast (neonatal) | Agonist | Biotech | Approved |
Hgene | FGFR2 | P21802 | DB10772 | Foreskin keratinocyte (neonatal) | Agonist | Biotech | Approved |
Hgene | FGFR2 | P21802 | DB10772 | Foreskin keratinocyte (neonatal) | Agonist | Biotech | Approved |
Hgene | FGFR2 | P21802 | DB10772 | Foreskin keratinocyte (neonatal) | Agonist | Biotech | Approved |
Hgene | FGFR2 | P21802 | DB10772 | Foreskin keratinocyte (neonatal) | Agonist | Biotech | Approved |
Hgene | FGFR2 | P21802 | DB01109 | Heparin | Small molecule | Approved|Investigational | |
Hgene | FGFR2 | P21802 | DB01109 | Heparin | Small molecule | Approved|Investigational | |
Hgene | FGFR2 | P21802 | DB01109 | Heparin | Small molecule | Approved|Investigational | |
Hgene | FGFR2 | P21802 | DB01109 | Heparin | Small molecule | Approved|Investigational | |
Hgene | FGFR2 | P21802 | DB08901 | Ponatinib | Inhibitor | Small molecule | Approved|Investigational |
Hgene | FGFR2 | P21802 | DB08901 | Ponatinib | Inhibitor | Small molecule | Approved|Investigational |
Hgene | FGFR2 | P21802 | DB08901 | Ponatinib | Inhibitor | Small molecule | Approved|Investigational |
Hgene | FGFR2 | P21802 | DB08901 | Ponatinib | Inhibitor | Small molecule | Approved|Investigational |
Hgene | FGFR2 | P21802 | DB09078 | Lenvatinib | Inhibitor | Small molecule | Approved|Investigational |
Hgene | FGFR2 | P21802 | DB09078 | Lenvatinib | Inhibitor | Small molecule | Approved|Investigational |
Hgene | FGFR2 | P21802 | DB09078 | Lenvatinib | Inhibitor | Small molecule | Approved|Investigational |
Hgene | FGFR2 | P21802 | DB09078 | Lenvatinib | Inhibitor | Small molecule | Approved|Investigational |
Hgene | FGFR2 | P21802 | DB12010 | Fostamatinib | Inhibitor | Small molecule | Approved|Investigational |
Hgene | FGFR2 | P21802 | DB12010 | Fostamatinib | Inhibitor | Small molecule | Approved|Investigational |
Hgene | FGFR2 | P21802 | DB12010 | Fostamatinib | Inhibitor | Small molecule | Approved|Investigational |
Hgene | FGFR2 | P21802 | DB12010 | Fostamatinib | Inhibitor | Small molecule | Approved|Investigational |
Hgene | FGFR2 | P21802 | DB12147 | Erdafitinib | Inhibitor | Small molecule | Approved|Investigational |
Hgene | FGFR2 | P21802 | DB12147 | Erdafitinib | Inhibitor | Small molecule | Approved|Investigational |
Hgene | FGFR2 | P21802 | DB12147 | Erdafitinib | Inhibitor | Small molecule | Approved|Investigational |
Hgene | FGFR2 | P21802 | DB12147 | Erdafitinib | Inhibitor | Small molecule | Approved|Investigational |
Hgene | FGFR2 | P21802 | DB15102 | Pemigatinib | Inhibitor | Small molecule | Approved|Investigational |
Hgene | FGFR2 | P21802 | DB15102 | Pemigatinib | Inhibitor | Small molecule | Approved|Investigational |
Hgene | FGFR2 | P21802 | DB15102 | Pemigatinib | Inhibitor | Small molecule | Approved|Investigational |
Hgene | FGFR2 | P21802 | DB15102 | Pemigatinib | Inhibitor | Small molecule | Approved|Investigational |
Hgene | FGFR2 | P21802 | DB15685 | Selpercatinib | Inhibitor | Small molecule | Approved|Investigational |
Hgene | FGFR2 | P21802 | DB15685 | Selpercatinib | Inhibitor | Small molecule | Approved|Investigational |
Hgene | FGFR2 | P21802 | DB15685 | Selpercatinib | Inhibitor | Small molecule | Approved|Investigational |
Hgene | FGFR2 | P21802 | DB15685 | Selpercatinib | Inhibitor | Small molecule | Approved|Investigational |
Hgene | FGFR2 | P21802 | DB15822 | Pralsetinib | Inhibitor | Small molecule | Approved|Investigational |
Hgene | FGFR2 | P21802 | DB15822 | Pralsetinib | Inhibitor | Small molecule | Approved|Investigational |
Hgene | FGFR2 | P21802 | DB15822 | Pralsetinib | Inhibitor | Small molecule | Approved|Investigational |
Hgene | FGFR2 | P21802 | DB15822 | Pralsetinib | Inhibitor | Small molecule | Approved|Investigational |
Hgene | FGFR2 | P21802 | DB01041 | Thalidomide | Antagonist | Small molecule | Approved|Investigational|Withdrawn |
Hgene | FGFR2 | P21802 | DB01041 | Thalidomide | Antagonist | Small molecule | Approved|Investigational|Withdrawn |
Hgene | FGFR2 | P21802 | DB01041 | Thalidomide | Antagonist | Small molecule | Approved|Investigational|Withdrawn |
Hgene | FGFR2 | P21802 | DB01041 | Thalidomide | Antagonist | Small molecule | Approved|Investigational|Withdrawn |
Tgene | FGFR2 | P21802 | DB00039 | Palifermin | Agonist|Binder | Biotech | Approved |
Tgene | FGFR2 | P21802 | DB00039 | Palifermin | Agonist|Binder | Biotech | Approved |
Tgene | FGFR2 | P21802 | DB00039 | Palifermin | Agonist|Binder | Biotech | Approved |
Tgene | FGFR2 | P21802 | DB00039 | Palifermin | Agonist|Binder | Biotech | Approved |
Tgene | FGFR2 | P21802 | DB08896 | Regorafenib | Inhibitor | Small molecule | Approved |
Tgene | FGFR2 | P21802 | DB08896 | Regorafenib | Inhibitor | Small molecule | Approved |
Tgene | FGFR2 | P21802 | DB08896 | Regorafenib | Inhibitor | Small molecule | Approved |
Tgene | FGFR2 | P21802 | DB08896 | Regorafenib | Inhibitor | Small molecule | Approved |
Tgene | FGFR2 | P21802 | DB09079 | Nintedanib | Inhibitor | Small molecule | Approved |
Tgene | FGFR2 | P21802 | DB09079 | Nintedanib | Inhibitor | Small molecule | Approved |
Tgene | FGFR2 | P21802 | DB09079 | Nintedanib | Inhibitor | Small molecule | Approved |
Tgene | FGFR2 | P21802 | DB09079 | Nintedanib | Inhibitor | Small molecule | Approved |
Tgene | FGFR2 | P21802 | DB10770 | Foreskin fibroblast (neonatal) | Agonist | Biotech | Approved |
Tgene | FGFR2 | P21802 | DB10770 | Foreskin fibroblast (neonatal) | Agonist | Biotech | Approved |
Tgene | FGFR2 | P21802 | DB10770 | Foreskin fibroblast (neonatal) | Agonist | Biotech | Approved |
Tgene | FGFR2 | P21802 | DB10770 | Foreskin fibroblast (neonatal) | Agonist | Biotech | Approved |
Tgene | FGFR2 | P21802 | DB10772 | Foreskin keratinocyte (neonatal) | Agonist | Biotech | Approved |
Tgene | FGFR2 | P21802 | DB10772 | Foreskin keratinocyte (neonatal) | Agonist | Biotech | Approved |
Tgene | FGFR2 | P21802 | DB10772 | Foreskin keratinocyte (neonatal) | Agonist | Biotech | Approved |
Tgene | FGFR2 | P21802 | DB10772 | Foreskin keratinocyte (neonatal) | Agonist | Biotech | Approved |
Tgene | FGFR2 | P21802 | DB01109 | Heparin | Small molecule | Approved|Investigational | |
Tgene | FGFR2 | P21802 | DB01109 | Heparin | Small molecule | Approved|Investigational | |
Tgene | FGFR2 | P21802 | DB01109 | Heparin | Small molecule | Approved|Investigational | |
Tgene | FGFR2 | P21802 | DB01109 | Heparin | Small molecule | Approved|Investigational | |
Tgene | FGFR2 | P21802 | DB08901 | Ponatinib | Inhibitor | Small molecule | Approved|Investigational |
Tgene | FGFR2 | P21802 | DB08901 | Ponatinib | Inhibitor | Small molecule | Approved|Investigational |
Tgene | FGFR2 | P21802 | DB08901 | Ponatinib | Inhibitor | Small molecule | Approved|Investigational |
Tgene | FGFR2 | P21802 | DB08901 | Ponatinib | Inhibitor | Small molecule | Approved|Investigational |
Tgene | FGFR2 | P21802 | DB09078 | Lenvatinib | Inhibitor | Small molecule | Approved|Investigational |
Tgene | FGFR2 | P21802 | DB09078 | Lenvatinib | Inhibitor | Small molecule | Approved|Investigational |
Tgene | FGFR2 | P21802 | DB09078 | Lenvatinib | Inhibitor | Small molecule | Approved|Investigational |
Tgene | FGFR2 | P21802 | DB09078 | Lenvatinib | Inhibitor | Small molecule | Approved|Investigational |
Tgene | FGFR2 | P21802 | DB12010 | Fostamatinib | Inhibitor | Small molecule | Approved|Investigational |
Tgene | FGFR2 | P21802 | DB12010 | Fostamatinib | Inhibitor | Small molecule | Approved|Investigational |
Tgene | FGFR2 | P21802 | DB12010 | Fostamatinib | Inhibitor | Small molecule | Approved|Investigational |
Tgene | FGFR2 | P21802 | DB12010 | Fostamatinib | Inhibitor | Small molecule | Approved|Investigational |
Tgene | FGFR2 | P21802 | DB12147 | Erdafitinib | Inhibitor | Small molecule | Approved|Investigational |
Tgene | FGFR2 | P21802 | DB12147 | Erdafitinib | Inhibitor | Small molecule | Approved|Investigational |
Tgene | FGFR2 | P21802 | DB12147 | Erdafitinib | Inhibitor | Small molecule | Approved|Investigational |
Tgene | FGFR2 | P21802 | DB12147 | Erdafitinib | Inhibitor | Small molecule | Approved|Investigational |
Tgene | FGFR2 | P21802 | DB15102 | Pemigatinib | Inhibitor | Small molecule | Approved|Investigational |
Tgene | FGFR2 | P21802 | DB15102 | Pemigatinib | Inhibitor | Small molecule | Approved|Investigational |
Tgene | FGFR2 | P21802 | DB15102 | Pemigatinib | Inhibitor | Small molecule | Approved|Investigational |
Tgene | FGFR2 | P21802 | DB15102 | Pemigatinib | Inhibitor | Small molecule | Approved|Investigational |
Tgene | FGFR2 | P21802 | DB15685 | Selpercatinib | Inhibitor | Small molecule | Approved|Investigational |
Tgene | FGFR2 | P21802 | DB15685 | Selpercatinib | Inhibitor | Small molecule | Approved|Investigational |
Tgene | FGFR2 | P21802 | DB15685 | Selpercatinib | Inhibitor | Small molecule | Approved|Investigational |
Tgene | FGFR2 | P21802 | DB15685 | Selpercatinib | Inhibitor | Small molecule | Approved|Investigational |
Tgene | FGFR2 | P21802 | DB15822 | Pralsetinib | Inhibitor | Small molecule | Approved|Investigational |
Tgene | FGFR2 | P21802 | DB15822 | Pralsetinib | Inhibitor | Small molecule | Approved|Investigational |
Tgene | FGFR2 | P21802 | DB15822 | Pralsetinib | Inhibitor | Small molecule | Approved|Investigational |
Tgene | FGFR2 | P21802 | DB15822 | Pralsetinib | Inhibitor | Small molecule | Approved|Investigational |
Tgene | FGFR2 | P21802 | DB01041 | Thalidomide | Antagonist | Small molecule | Approved|Investigational|Withdrawn |
Tgene | FGFR2 | P21802 | DB01041 | Thalidomide | Antagonist | Small molecule | Approved|Investigational|Withdrawn |
Tgene | FGFR2 | P21802 | DB01041 | Thalidomide | Antagonist | Small molecule | Approved|Investigational|Withdrawn |
Tgene | FGFR2 | P21802 | DB01041 | Thalidomide | Antagonist | Small molecule | Approved|Investigational|Withdrawn |
Top |
Related Diseases for FGFR2-FGFR2 |
Diseases associated with fusion partners. (DisGeNet 4.0) |
Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
Hgene | FGFR2 | C2931196 | Craniofacial dysostosis type 1 | 23 | CTD_human;GENOMICS_ENGLAND;UNIPROT |
Hgene | FGFR2 | C0220658 | Pfeiffer Syndrome | 21 | CTD_human;GENOMICS_ENGLAND;UNIPROT |
Hgene | FGFR2 | C0001193 | Apert syndrome | 19 | CTD_human;GENOMICS_ENGLAND;ORPHANET;UNIPROT |
Hgene | FGFR2 | C0795998 | JACKSON-WEISS SYNDROME | 10 | CTD_human;GENOMICS_ENGLAND;ORPHANET;UNIPROT |
Hgene | FGFR2 | C0175699 | Saethre-Chotzen Syndrome | 8 | CTD_human;GENOMICS_ENGLAND;ORPHANET |
Hgene | FGFR2 | C1852406 | Cutis Gyrata Syndrome of Beare And Stevenson | 8 | CTD_human;GENOMICS_ENGLAND;ORPHANET;UNIPROT |
Hgene | FGFR2 | C2936791 | Antley-Bixler Syndrome, Autosomal Dominant | 7 | CTD_human;GENOMICS_ENGLAND;ORPHANET;UNIPROT |
Hgene | FGFR2 | C1510455 | Acrocephalosyndactylia | 6 | CTD_human;ORPHANET |
Hgene | FGFR2 | C0265269 | Lacrimoauriculodentodigital syndrome | 5 | CTD_human;GENOMICS_ENGLAND;ORPHANET;UNIPROT |
Hgene | FGFR2 | C0010278 | Craniosynostosis | 4 | CTD_human;GENOMICS_ENGLAND |
Hgene | FGFR2 | C1863389 | Apert-Crouzon Disease | 4 | CTD_human |
Hgene | FGFR2 | C1865070 | SCAPHOCEPHALY, MAXILLARY RETRUSION, AND MENTAL RETARDATION | 4 | CTD_human;GENOMICS_ENGLAND;ORPHANET;UNIPROT |
Hgene | FGFR2 | C0006142 | Malignant neoplasm of breast | 3 | CTD_human;UNIPROT |
Hgene | FGFR2 | C0030044 | Acrocephaly | 3 | CTD_human |
Hgene | FGFR2 | C0036341 | Schizophrenia | 3 | PSYGENET |
Hgene | FGFR2 | C0221356 | Brachycephaly | 3 | CTD_human |
Hgene | FGFR2 | C0265534 | Scaphycephaly | 3 | CTD_human |
Hgene | FGFR2 | C0265535 | Trigonocephaly | 3 | CTD_human |
Hgene | FGFR2 | C0376634 | Craniofacial Abnormalities | 3 | CTD_human |
Hgene | FGFR2 | C0678222 | Breast Carcinoma | 3 | CTD_human |
Hgene | FGFR2 | C1257931 | Mammary Neoplasms, Human | 3 | CTD_human |
Hgene | FGFR2 | C1458155 | Mammary Neoplasms | 3 | CTD_human |
Hgene | FGFR2 | C1833340 | Synostotic Posterior Plagiocephaly | 3 | CTD_human |
Hgene | FGFR2 | C1860819 | Metopic synostosis | 3 | CTD_human |
Hgene | FGFR2 | C2931150 | Synostotic Anterior Plagiocephaly | 3 | CTD_human |
Hgene | FGFR2 | C3281247 | BENT BONE DYSPLASIA SYNDROME | 3 | CTD_human;GENOMICS_ENGLAND;ORPHANET;UNIPROT |
Hgene | FGFR2 | C4551902 | Craniosynostosis, Type 1 | 3 | CTD_human |
Hgene | FGFR2 | C4704874 | Mammary Carcinoma, Human | 3 | CTD_human |
Hgene | FGFR2 | C0008925 | Cleft Palate | 2 | CTD_human |
Hgene | FGFR2 | C0011570 | Mental Depression | 2 | PSYGENET |
Hgene | FGFR2 | C0011581 | Depressive disorder | 2 | PSYGENET |
Hgene | FGFR2 | C0024623 | Malignant neoplasm of stomach | 2 | CGI;CTD_human |
Hgene | FGFR2 | C0038356 | Stomach Neoplasms | 2 | CGI;CTD_human |
Hgene | FGFR2 | C1708349 | Hereditary Diffuse Gastric Cancer | 2 | CTD_human |
Hgene | FGFR2 | C1837218 | Cleft palate, isolated | 2 | CTD_human |
Hgene | FGFR2 | C0000772 | Multiple congenital anomalies | 1 | CTD_human |
Hgene | FGFR2 | C0003090 | Ankylosis | 1 | CTD_human |
Hgene | FGFR2 | C0005586 | Bipolar Disorder | 1 | PSYGENET |
Hgene | FGFR2 | C0008924 | Cleft upper lip | 1 | CTD_human |
Hgene | FGFR2 | C0010273 | Craniofacial Dysostosis | 1 | CTD_human |
Hgene | FGFR2 | C0011757 | Developmental Coordination Disorder | 1 | CTD_human |
Hgene | FGFR2 | C0014170 | Endometrial Neoplasms | 1 | CTD_human |
Hgene | FGFR2 | C0018553 | Hamartoma Syndrome, Multiple | 1 | CTD_human |
Hgene | FGFR2 | C0020796 | Profound Mental Retardation | 1 | CTD_human |
Hgene | FGFR2 | C0023890 | Liver Cirrhosis | 1 | CTD_human |
Hgene | FGFR2 | C0024121 | Lung Neoplasms | 1 | CTD_human |
Hgene | FGFR2 | C0025363 | Mental Retardation, Psychosocial | 1 | CTD_human |
Hgene | FGFR2 | C0026613 | Motor Skills Disorders | 1 | CTD_human |
Hgene | FGFR2 | C0033975 | Psychotic Disorders | 1 | PSYGENET |
Hgene | FGFR2 | C0037268 | Skin Abnormalities | 1 | CTD_human |
Hgene | FGFR2 | C0037274 | Dermatologic disorders | 1 | CTD_human |
Hgene | FGFR2 | C0038219 | Status Dysraphicus | 1 | CTD_human |
Hgene | FGFR2 | C0040427 | Tooth Abnormalities | 1 | CTD_human |
Hgene | FGFR2 | C0080178 | Spina Bifida | 1 | CTD_human |
Hgene | FGFR2 | C0152423 | Congenital small ears | 1 | GENOMICS_ENGLAND |
Hgene | FGFR2 | C0206698 | Cholangiocarcinoma | 1 | CTD_human |
Hgene | FGFR2 | C0206762 | Limb Deformities, Congenital | 1 | CTD_human |
Hgene | FGFR2 | C0239946 | Fibrosis, Liver | 1 | CTD_human |
Hgene | FGFR2 | C0242379 | Malignant neoplasm of lung | 1 | CTD_human |
Hgene | FGFR2 | C0265326 | Bannayan-Riley-Ruvalcaba Syndrome | 1 | CTD_human |
Hgene | FGFR2 | C0266508 | Rachischisis | 1 | CTD_human |
Hgene | FGFR2 | C0345905 | Intrahepatic Cholangiocarcinoma | 1 | CTD_human |
Hgene | FGFR2 | C0349204 | Nonorganic psychosis | 1 | PSYGENET |
Hgene | FGFR2 | C0391826 | Lhermitte-Duclos disease | 1 | CTD_human |
Hgene | FGFR2 | C0476089 | Endometrial Carcinoma | 1 | CGI;CTD_human |
Hgene | FGFR2 | C0524730 | Odontome | 1 | CTD_human |
Hgene | FGFR2 | C0699791 | Stomach Carcinoma | 1 | CGI;GENOMICS_ENGLAND |
Hgene | FGFR2 | C0917816 | Mental deficiency | 1 | CTD_human |
Hgene | FGFR2 | C1450010 | Plagiocephaly, Nonsynostotic | 1 | CTD_human |
Hgene | FGFR2 | C1860042 | Antley-Bixler Syndrome with Disordered Steroidogenesis | 1 | CTD_human |
Hgene | FGFR2 | C1867564 | SCAPHOCEPHALY AND AXENFELD-RIEGER ANOMALY | 1 | GENOMICS_ENGLAND |
Hgene | FGFR2 | C1959582 | PTEN Hamartoma Tumor Syndrome | 1 | CTD_human |
Hgene | FGFR2 | C2350233 | Antley-Bixler Syndrome Phenotype | 1 | CTD_human |
Hgene | FGFR2 | C3267076 | Familial scaphocephaly syndrome | 1 | GENOMICS_ENGLAND |
Hgene | FGFR2 | C3714756 | Intellectual Disability | 1 | CTD_human |
Hgene | FGFR2 | C3805278 | Extrahepatic Cholangiocarcinoma | 1 | CTD_human |
Tgene | C2931196 | Craniofacial dysostosis type 1 | 23 | CTD_human;GENOMICS_ENGLAND;UNIPROT | |
Tgene | C0220658 | Pfeiffer Syndrome | 21 | CTD_human;GENOMICS_ENGLAND;UNIPROT | |
Tgene | C0001193 | Apert syndrome | 19 | CTD_human;GENOMICS_ENGLAND;ORPHANET;UNIPROT | |
Tgene | C0795998 | JACKSON-WEISS SYNDROME | 10 | CTD_human;GENOMICS_ENGLAND;ORPHANET;UNIPROT | |
Tgene | C0175699 | Saethre-Chotzen Syndrome | 8 | CTD_human;GENOMICS_ENGLAND;ORPHANET | |
Tgene | C1852406 | Cutis Gyrata Syndrome of Beare And Stevenson | 8 | CTD_human;GENOMICS_ENGLAND;ORPHANET;UNIPROT | |
Tgene | C2936791 | Antley-Bixler Syndrome, Autosomal Dominant | 7 | CTD_human;GENOMICS_ENGLAND;ORPHANET;UNIPROT | |
Tgene | C1510455 | Acrocephalosyndactylia | 6 | CTD_human;ORPHANET | |
Tgene | C0265269 | Lacrimoauriculodentodigital syndrome | 5 | CTD_human;GENOMICS_ENGLAND;ORPHANET;UNIPROT | |
Tgene | C0010278 | Craniosynostosis | 4 | CTD_human;GENOMICS_ENGLAND | |
Tgene | C1863389 | Apert-Crouzon Disease | 4 | CTD_human | |
Tgene | C1865070 | SCAPHOCEPHALY, MAXILLARY RETRUSION, AND MENTAL RETARDATION | 4 | CTD_human;GENOMICS_ENGLAND;ORPHANET;UNIPROT | |
Tgene | C0006142 | Malignant neoplasm of breast | 3 | CTD_human;UNIPROT | |
Tgene | C0030044 | Acrocephaly | 3 | CTD_human | |
Tgene | C0036341 | Schizophrenia | 3 | PSYGENET | |
Tgene | C0221356 | Brachycephaly | 3 | CTD_human | |
Tgene | C0265534 | Scaphycephaly | 3 | CTD_human | |
Tgene | C0265535 | Trigonocephaly | 3 | CTD_human | |
Tgene | C0376634 | Craniofacial Abnormalities | 3 | CTD_human | |
Tgene | C0678222 | Breast Carcinoma | 3 | CTD_human | |
Tgene | C1257931 | Mammary Neoplasms, Human | 3 | CTD_human | |
Tgene | C1458155 | Mammary Neoplasms | 3 | CTD_human | |
Tgene | C1833340 | Synostotic Posterior Plagiocephaly | 3 | CTD_human | |
Tgene | C1860819 | Metopic synostosis | 3 | CTD_human | |
Tgene | C2931150 | Synostotic Anterior Plagiocephaly | 3 | CTD_human | |
Tgene | C3281247 | BENT BONE DYSPLASIA SYNDROME | 3 | CTD_human;GENOMICS_ENGLAND;ORPHANET;UNIPROT | |
Tgene | C4551902 | Craniosynostosis, Type 1 | 3 | CTD_human | |
Tgene | C4704874 | Mammary Carcinoma, Human | 3 | CTD_human | |
Tgene | C0008925 | Cleft Palate | 2 | CTD_human | |
Tgene | C0011570 | Mental Depression | 2 | PSYGENET | |
Tgene | C0011581 | Depressive disorder | 2 | PSYGENET | |
Tgene | C0024623 | Malignant neoplasm of stomach | 2 | CGI;CTD_human | |
Tgene | C0038356 | Stomach Neoplasms | 2 | CGI;CTD_human | |
Tgene | C1708349 | Hereditary Diffuse Gastric Cancer | 2 | CTD_human | |
Tgene | C1837218 | Cleft palate, isolated | 2 | CTD_human | |
Tgene | C0000772 | Multiple congenital anomalies | 1 | CTD_human | |
Tgene | C0003090 | Ankylosis | 1 | CTD_human | |
Tgene | C0005586 | Bipolar Disorder | 1 | PSYGENET | |
Tgene | C0008924 | Cleft upper lip | 1 | CTD_human | |
Tgene | C0010273 | Craniofacial Dysostosis | 1 | CTD_human | |
Tgene | C0011757 | Developmental Coordination Disorder | 1 | CTD_human | |
Tgene | C0014170 | Endometrial Neoplasms | 1 | CTD_human | |
Tgene | C0018553 | Hamartoma Syndrome, Multiple | 1 | CTD_human | |
Tgene | C0020796 | Profound Mental Retardation | 1 | CTD_human | |
Tgene | C0023890 | Liver Cirrhosis | 1 | CTD_human | |
Tgene | C0024121 | Lung Neoplasms | 1 | CTD_human | |
Tgene | C0025363 | Mental Retardation, Psychosocial | 1 | CTD_human | |
Tgene | C0026613 | Motor Skills Disorders | 1 | CTD_human | |
Tgene | C0033975 | Psychotic Disorders | 1 | PSYGENET | |
Tgene | C0037268 | Skin Abnormalities | 1 | CTD_human | |
Tgene | C0037274 | Dermatologic disorders | 1 | CTD_human | |
Tgene | C0038219 | Status Dysraphicus | 1 | CTD_human | |
Tgene | C0040427 | Tooth Abnormalities | 1 | CTD_human | |
Tgene | C0080178 | Spina Bifida | 1 | CTD_human | |
Tgene | C0152423 | Congenital small ears | 1 | GENOMICS_ENGLAND | |
Tgene | C0206698 | Cholangiocarcinoma | 1 | CTD_human | |
Tgene | C0206762 | Limb Deformities, Congenital | 1 | CTD_human | |
Tgene | C0239946 | Fibrosis, Liver | 1 | CTD_human | |
Tgene | C0242379 | Malignant neoplasm of lung | 1 | CTD_human | |
Tgene | C0265326 | Bannayan-Riley-Ruvalcaba Syndrome | 1 | CTD_human | |
Tgene | C0266508 | Rachischisis | 1 | CTD_human | |
Tgene | C0345905 | Intrahepatic Cholangiocarcinoma | 1 | CTD_human | |
Tgene | C0349204 | Nonorganic psychosis | 1 | PSYGENET | |
Tgene | C0391826 | Lhermitte-Duclos disease | 1 | CTD_human | |
Tgene | C0476089 | Endometrial Carcinoma | 1 | CGI;CTD_human | |
Tgene | C0524730 | Odontome | 1 | CTD_human | |
Tgene | C0699791 | Stomach Carcinoma | 1 | CGI;GENOMICS_ENGLAND | |
Tgene | C0917816 | Mental deficiency | 1 | CTD_human | |
Tgene | C1450010 | Plagiocephaly, Nonsynostotic | 1 | CTD_human | |
Tgene | C1860042 | Antley-Bixler Syndrome with Disordered Steroidogenesis | 1 | CTD_human | |
Tgene | C1867564 | SCAPHOCEPHALY AND AXENFELD-RIEGER ANOMALY | 1 | GENOMICS_ENGLAND | |
Tgene | C1959582 | PTEN Hamartoma Tumor Syndrome | 1 | CTD_human | |
Tgene | C2350233 | Antley-Bixler Syndrome Phenotype | 1 | CTD_human | |
Tgene | C3267076 | Familial scaphocephaly syndrome | 1 | GENOMICS_ENGLAND | |
Tgene | C3714756 | Intellectual Disability | 1 | CTD_human | |
Tgene | C3805278 | Extrahepatic Cholangiocarcinoma | 1 | CTD_human |